MOH approval received for Rare Genetic Disorder study in Russia
The regulatory approval to conduct CNS Pediatric study in Russia was received by GCT in under 60 days.
This Phase III study in children and young adults with a rare genetic mutation in the X-chromosome was awarded to GCT earlier this year. Study aims to recruit up to 20 patients with this rare and debilitating disease in Russia alone. GCT is responsible for the site management, providing the full service clinical operations support, logistics and regulatory services.
September 11, 2019
Phase II gastroenterology global study expansion to Ukraine and Russia
GCT has been awarded a new major project by Kangen Pharmaceuticals – a Phase II parallel-group dose-ranging
study to evaluate the safety and efficacy of the drug compared to placebo in patients with chronic pancreatitis.
August 29, 2019
Meet our clients
All trademarks, brand names and logotypes are intellectual property of their respective owners.